Specialized Disclosure Report (sd)
31 Maio 2023 - 03:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form SD
SPECIALIZED
DISCLOSURE REPORT
Abbott Laboratories
(Exact Name of Registrant as Specified in Charter)
Illinois |
|
1-2189 |
|
36-0698440 |
(State
or Other Jurisdiction |
|
(Commission
File No.) |
|
(I.R.S.
Employer |
of
Incorporation) |
|
|
|
Identification
Number) |
100
Abbott Park Road, Abbott Park, IL |
|
60064-6400 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Hubert Allen (224)
667-6100
(Name and telephone number, including area code, of the person to
contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to
which this form is being filed, and provide the period to which the
information in this form applies:
x Rule 13p-1
under the Securities Exchange Act (17 CFR 240.13p-1) for the
reporting period from January 1 to December 31, 2022
Section 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Abbott Laboratories (Abbott) is filing a Conflict Minerals Report
as an exhibit to this specialized disclosure report and is
providing that report on Abbott’s publicly available Internet
website at
http://www.abbott.com/policies/conflict-minerals.html.
Abbott’s determination and related disclosures relating to
materials that may come from recycled and scrap sources are
included in our Conflict Minerals Report and are incorporated by
reference herein.
Item 1.02 Exhibit
The Conflict Minerals Report required by Item 1.01 is filed as an
exhibit to this Form SD.
Section 2 — Exhibits
Item 2.01 Exhibits
The following exhibit is filed as a part of this report.
Exhibit 1.01 - Conflict Minerals Report as required by Items
1.01 and 1.02 of this Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the duly authorized undersigned.
Abbott Laboratories
(Registrant)
/s/
Robert E. Funck, Jr. |
|
May
31, 2023 |
By
(Signature and Title) |
|
(Date) |
Robert E. Funck, Jr.
Executive Vice President, Finance & Chief Financial
Officer
EXHIBIT INDEX
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Set 2023 até Out 2023
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Out 2022 até Out 2023